OncoZenge
5.70 SEK
-1.72 %
Less than 1K followers
ONCOZ
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for OncoZenge
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | 2.7 | |||||
| growth-% | ||||||
| EBITDA | -0.8 | -4.9 | -43.6 | -15.9 | -8.7 | - |
| EBIT | -0.8 | -4.9 | -43.6 | -15.9 | -8.7 | -15.8 |
| Profit before taxes | -0.8 | -4.9 | -43.6 | -15.9 | -8.7 | -15.9 |
| Net income | -0.8 | -3.9 | -46.7 | -15.9 | -8.7 | -15.9 |
| EPS | -0.05 | -0.33 | -3.98 | -1.36 | -0.74 | -1.31 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| EBITDA-% | ||||||
| EBIT-% | -592.6 % | |||||
| ROE | -2.7 % | -4.8 % | -137.3 % | -85.3 % | -87.3 % | -188.0 % |
| ROI | -2.1 % | -4.6 % | -126.5 % | -78.2 % | -76.0 % | -65.3 % |